Clinical Trials
3 trialsNCT05797168 2026-06-03
FONTANA
AstraZeneca
Phase 1/2 Recruiting
NCT05703516 2026-06-01
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Novartis
Recruiting
NCT04248829 2026-05-28
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Phase 3 Completed